Skip to main content

Drug Interactions between Capastat and miglustat

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

No interactions were found between Capastat and miglustat. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Capastat

A total of 164 drugs are known to interact with Capastat.

miglustat

A total of 1 drugs are known to interact with miglustat.

Drug and food interactions

Moderate

migLUstat food

Applies to: miglustat

Food may delay and/or reduce the absorption of miglustat (brand name Opfolda). This brand of miglustat should be administered on an empty stomach with unsweetened beverages (e.G., water, tea or coffee with no cream, sugar, or sweeteners) at least 2 hours before or 2 hours after food. Other miglustat products (brand names Zavesca and Yargesa) can be taken with or without food. MigLUstat may also cause diarrhea. Talk to your doctor if you are experiencing diarrhea or other digestive problems. Your doctor may suggest a dose adjustment, taking your medication between meals, and/or modifying your diet to have less sucrose, lactose, and other carbohydrates. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer